triazoles has been researched along with levodopa in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 2 (6.45) | 18.2507 |
| 2000's | 16 (51.61) | 29.6817 |
| 2010's | 11 (35.48) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Merican, Z; Nott, MW | 1 |
| Simpson, JS | 1 |
| Fenu, S; Morelli, M; Ongini, E; Pinna, A | 1 |
| Fenu, S; Morelli, M; Pinna, A | 1 |
| Konieczny, J; Lorenc-Koci, E; Wardas, J | 1 |
| Morelli, M; Pinna, A | 1 |
| Carta, AR; Cauli, O; Morelli, M; Pinna, A | 1 |
| Carta, AR; Morelli, M; Pinna, A; Tronci, E | 1 |
| Bastia, E; Chen, JF; Fredduzzi, S; Moratalla, R; Ongini, E; Schwarzschild, MA; Yu, L | 1 |
| Casadevall, A; Cleare, W; Nosanchuk, JD; van Duin, D; Zaragoza, O | 1 |
| Agnati, LF; Antonelli, T; Ferraro, L; Ferré, S; Franco, R; Fuxe, K; Kehr, J; Sandager Nielsen, K; Scheel-Krüger, J; Tanganelli, S | 1 |
| Dziubina, A; Gołembiowska, K | 3 |
| Bédard, PJ; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M | 1 |
| Carminati, P; Jackson, MJ; Jenner, P; Johnson, L; Rose, S; Smith, LA; Stockwell, K | 1 |
| Jenner, P; Ramsay Croft, N; Rose, S | 1 |
| Asai, M; Matsuya, T; Miyoshi, S; Mizoguchi, H; Murakami, Y; Nagai, T; Nishimura, S; Noda, A; Sato, K; Takuma, K; Yamada, K | 1 |
| Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E | 1 |
| Borsini, F; Morelli, M; Pinna, A; Pontis, S | 1 |
| Dziubina, A; Gołembiowska, K; Kamińska, K; Kowalska, M | 1 |
| Cristalli, G; Morelli, M; Pinna, A; Pontis, S; Schintu, N; Simola, N; Tronci, E; Volpini, R | 1 |
| Cantillon, M; Hauser, RA; Huyck, S; Micheli, F; Mok, V; Onofrj, M; Pourcher, E; Wolski, K | 1 |
| Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N | 1 |
| Egecioglu, E; Jerlhag, E; Prieto-Garcia, L; Studer, E; Westberg, L | 1 |
| Downey, P; Michel, A; Nicolas, JM; Scheller, D | 1 |
| Capece, R; Hauser, RA; Hewitt, D; Ho, TW; Huyck, SB; Lines, C; Michelson, D; Rascol, O; Sklar, P; Stocchi, F | 1 |
| Bezard, E; Carta, M; Costa, G; Fidalgo, C; Ko, WK; Li, Q; Morelli, M; Pinna, A; Simola, N; Tabrizi, MA; Tronci, E | 1 |
| A Figge, D; Standaert, DG | 1 |
| Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG | 1 |
| Contu, L; Costa, G; Morelli, M; Pinna, A; Serra, M | 1 |
2 trial(s) available for triazoles and levodopa
| Article | Year |
|---|---|
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Pyrimidines; Triazoles | 2011 |
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; International Cooperation; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Pyrimidines; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles | 2015 |
29 other study(ies) available for triazoles and levodopa
| Article | Year |
|---|---|
Effects of isoprenaline, levodopa and a phosphodiesterase inhibitor (ICI 63,197) on cyclic AMP levels and contractions of soleus muscles in anesthetized cats.
Topics: Anesthesia; Animals; Cats; Cyclic AMP; Female; Isoproterenol; Levodopa; Male; Muscle Contraction; Muscles; Phosphodiesterase Inhibitors; Pyrimidines; Triazoles | 1981 |
Familial akathisia and depression treated with nefazodone.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Piperazines; Restless Legs Syndrome; Selective Serotonin Reuptake Inhibitors; Triazoles | 1996 |
Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Behavior, Animal; Brain Diseases; Dopamine Agonists; Drug Synergism; Gene Expression; Genes, fos; Levodopa; Male; Oxidopamine; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Dopamine D2; Substantia Nigra; Triazoles | 1997 |
Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Dopamine Agents; Drug Tolerance; Levodopa; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Stereotyped Behavior; Sympathectomy, Chemical; Triazoles | 2001 |
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Ankle Joint; Dopamine Agents; Dopamine Antagonists; Drug Combinations; Electromyography; Haloperidol; Levodopa; Male; Muscle Contraction; Muscle Rigidity; Muscle, Skeletal; Neostriatum; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Purinergic P1; Reserpine; Triazoles | 2001 |
Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Denervation; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Levodopa; Male; Motor Activity; Neostriatum; Neural Pathways; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Substantia Nigra; Sympatholytics; Triazoles | 2001 |
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.
Topics: Animals; Corpus Striatum; Denervation; Dopamine; Dopamine Agents; Dynorphins; Enkephalins; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Neuroprotective Agents; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; RNA, Messenger; Triazoles | 2002 |
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Denervation; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine; RNA, Messenger; Time; Triazoles | 2003 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Synapses; Triazoles | 2003 |
Effects of voriconazole on Cryptococcus neoformans.
Topics: Amphotericin B; Animals; Antibodies, Monoclonal; Antifungal Agents; Cell Line; Cryptococcus neoformans; Levodopa; Melanins; Mice; Microbial Sensitivity Tests; Microscopy, Electron; Phagocytosis; Polysaccharides; Pyrimidines; Triazoles; Voriconazole | 2004 |
Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Levodopa; Male; Mice; Nerve Net; Neuronal Plasticity; Parkinson Disease; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Dopamine D2; Triazoles | 2004 |
Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Area Under Curve; Brain Chemistry; Chromatography, High Pressure Liquid; Corpus Striatum; Denervation; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Malonates; Methyltyrosines; Rats; Rats, Wistar; Receptor, Adenosine A2A; Reserpine; Serotonin; Substantia Nigra; Time Factors; Triazines; Triazoles; Xanthines | 2004 |
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzoxazoles; Denervation; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Image Processing, Computer-Assisted; In Situ Hybridization; Levodopa; Macaca fascicularis; Motor Activity; Neuroprotective Agents; Oligonucleotide Probes; Ovariectomy; Parkinson Disease, Secondary; Piperidines; Pyrimidines; Receptor, Adenosine A2A; Receptors, N-Methyl-D-Aspartate; Triazoles | 2006 |
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Callithrix; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Skills; MPTP Poisoning; Triazoles | 2006 |
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Exploratory Behavior; Levodopa; Male; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Sympatholytics; Triazoles | 2007 |
Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred ICR; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Pyrimidines; Receptor, Adenosine A2A; Rotation; Triazoles | 2007 |
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dynorphins; Enkephalins; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tacrine; Tremor; Triazoles | 2007 |
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Dihydroxyphenylalanine; Dopamine Agents; Functional Laterality; Immunohistochemistry; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Triazoles; Tyrosine 3-Monooxygenase; Vibrissae | 2007 |
Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Area Under Curve; Benserazide; Catalepsy; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Homovanillic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Rats; Rats, Wistar; Time Factors; Triazines; Triazoles; Xanthines | 2009 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Chemistry; CD11b Antigen; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Jaw; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Movement; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotarod Performance Test; Time Factors; Triazoles; Vibrissae | 2010 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles | 2012 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase | 2012 |
The effect of adenosine A(2A) receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Caffeine; Corpus Striatum; Dopamine; Dopamine Agents; Extracellular Space; Glutamic Acid; Homovanillic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Oxidative Stress; Rats; Rats, Wistar; Reserpine; Triazines; Triazoles; Vesicular Monoamine Transport Proteins | 2012 |
The role of ghrelin signalling for sexual behaviour in male mice.
Topics: 5-Hydroxytryptophan; Analysis of Variance; Animals; Central Nervous System Agents; Conditioning, Psychological; Dopamine Agents; Female; Ghrelin; Glycine; Levodopa; Male; Mating Preference, Animal; Mice; Mice, Knockout; Motivation; Reaction Time; Receptors, Ghrelin; Sexual Behavior, Animal; Signal Transduction; Triazoles | 2016 |
Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Benzothiazoles; Drug Therapy, Combination; Levodopa; Mass Spectrometry; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Purines; Pyrimidines; Rats; Receptors, N-Methyl-D-Aspartate; Triazoles | 2014 |
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Parkinson Disease; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Triazoles | 2016 |
Dysregulation of BET proteins in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Azepines; Chromatin Immunoprecipitation; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Domains; Proteins; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Triazoles | 2017 |
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychoses, Substance-Induced; Triazoles | 2018 |
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Caudate Nucleus; Dyskinesia, Drug-Induced; Glial Fibrillary Acidic Protein; Interleukin-10; Interleukin-1beta; Levodopa; Microfilament Proteins; Neuroinflammatory Diseases; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Piperazines; Putamen; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Agonists; Triazoles; Tumor Necrosis Factor-alpha | 2021 |